| pubmed-article:15832355 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15832355 | lifeskim:mentions | umls-concept:C0021289 | lld:lifeskim |
| pubmed-article:15832355 | lifeskim:mentions | umls-concept:C0041243 | lld:lifeskim |
| pubmed-article:15832355 | lifeskim:mentions | umls-concept:C2911653 | lld:lifeskim |
| pubmed-article:15832355 | lifeskim:mentions | umls-concept:C0042295 | lld:lifeskim |
| pubmed-article:15832355 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:15832355 | pubmed:dateCreated | 2005-5-26 | lld:pubmed |
| pubmed-article:15832355 | pubmed:abstractText | Following cystic fibrosis (CF) neonatal screening implementation, a high frequency of heterozygotes has been reported among neonates with elevated immunoreactive trypsinogen (IRT) and normal sweat chloride levels. We studied the relationship between normal IRT values and CF heterozygosity: 10,000 neonates were screened for CF by IRT measurement and tested for 40 CF mutations; the 294 carriers detected were coupled with newborns negative to the same genetic testing, and the two groups' IRT levels compared. Heterozygotes had higher IRT levels than their controls (mean 35.32 vs. 27.58 microg/L, P<0.001). Even within normal trypsinogen range, the probability of being a CF carrier increases with neonatal IRT concentration. | lld:pubmed |
| pubmed-article:15832355 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15832355 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15832355 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15832355 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15832355 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15832355 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15832355 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15832355 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:15832355 | pubmed:issn | 1552-4825 | lld:pubmed |
| pubmed-article:15832355 | pubmed:author | pubmed-author:ZacchelloFran... | lld:pubmed |
| pubmed-article:15832355 | pubmed:author | pubmed-author:ZanollaLuisaL | lld:pubmed |
| pubmed-article:15832355 | pubmed:author | pubmed-author:CastellaniCar... | lld:pubmed |
| pubmed-article:15832355 | pubmed:author | pubmed-author:DechecchiMari... | lld:pubmed |
| pubmed-article:15832355 | pubmed:author | pubmed-author:AssaelBaroukh... | lld:pubmed |
| pubmed-article:15832355 | pubmed:author | pubmed-author:PicciLuigiL | lld:pubmed |
| pubmed-article:15832355 | pubmed:author | pubmed-author:ScarpaMaurizi... | lld:pubmed |
| pubmed-article:15832355 | pubmed:copyrightInfo | Copyright (c) 2005 Wiley-Liss, Inc. | lld:pubmed |
| pubmed-article:15832355 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15832355 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:15832355 | pubmed:volume | 135 | lld:pubmed |
| pubmed-article:15832355 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15832355 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15832355 | pubmed:pagination | 142-4 | lld:pubmed |
| pubmed-article:15832355 | pubmed:dateRevised | 2009-11-19 | lld:pubmed |
| pubmed-article:15832355 | pubmed:meshHeading | pubmed-meshheading:15832355... | lld:pubmed |
| pubmed-article:15832355 | pubmed:meshHeading | pubmed-meshheading:15832355... | lld:pubmed |
| pubmed-article:15832355 | pubmed:meshHeading | pubmed-meshheading:15832355... | lld:pubmed |
| pubmed-article:15832355 | pubmed:meshHeading | pubmed-meshheading:15832355... | lld:pubmed |
| pubmed-article:15832355 | pubmed:meshHeading | pubmed-meshheading:15832355... | lld:pubmed |
| pubmed-article:15832355 | pubmed:meshHeading | pubmed-meshheading:15832355... | lld:pubmed |
| pubmed-article:15832355 | pubmed:meshHeading | pubmed-meshheading:15832355... | lld:pubmed |
| pubmed-article:15832355 | pubmed:meshHeading | pubmed-meshheading:15832355... | lld:pubmed |
| pubmed-article:15832355 | pubmed:meshHeading | pubmed-meshheading:15832355... | lld:pubmed |
| pubmed-article:15832355 | pubmed:meshHeading | pubmed-meshheading:15832355... | lld:pubmed |
| pubmed-article:15832355 | pubmed:meshHeading | pubmed-meshheading:15832355... | lld:pubmed |
| pubmed-article:15832355 | pubmed:meshHeading | pubmed-meshheading:15832355... | lld:pubmed |
| pubmed-article:15832355 | pubmed:meshHeading | pubmed-meshheading:15832355... | lld:pubmed |
| pubmed-article:15832355 | pubmed:year | 2005 | lld:pubmed |
| pubmed-article:15832355 | pubmed:articleTitle | Cystic fibrosis carriers have higher neonatal immunoreactive trypsinogen values than non-carriers. | lld:pubmed |
| pubmed-article:15832355 | pubmed:affiliation | Cystic Fibrosis Centre, Azienda Ospedaliera di Verona, Verona, Italy. carlo.castellani@mail.azosp.vr.it | lld:pubmed |
| pubmed-article:15832355 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:15832355 | pubmed:publicationType | Comparative Study | lld:pubmed |
| entrez-gene:1080 | entrezgene:pubmed | pubmed-article:15832355 | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:15832355 | lld:entrezgene |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15832355 | lld:pubmed |
